Alexander I Damanakis1, Sabine Eckhardt1, Annette Wunderlich1, Silvia Roth1, Thaddeus T Wissniowski2, Detlef K Bartsch1, Pietro Di Fazio3. 1. Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35043, Marburg, Germany. 2. Division of Gastroenterology and Endocrinology, Philipps University Marburg, Baldingerstrasse, 35043, Marburg, Germany. 3. Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35043, Marburg, Germany. difazio@med.uni-marburg.de.
Abstract
PURPOSE: Thyroid cancer (TC), the most common endocrine malignancy, increases its incidence worldwide. MicroRNAs have been shown to be abnormally expressed in tumors and could represent valid diagnostic markers for patients affected by TC. Our aim was to analyze the expression of tumorsuppressor hsa-let7b-5p and hsa-let7f-5p, together with their predicted targets SLC5A5 (NIS) and HMGA2, in papillary (PTC), follicular (FTC) and anaplastic (ATC). METHODS: 8 FTC, 14 PTC, 12 ATC and three normal thyroid tissue samples were analyzed for the expression of pre-let7b, hsa-let7b-5p and hsa-let7f-5p as SLC5A5 and HMGA2 by RT-qPCR. Data were analyzed by REST 2008. RESULTS: FTC patients showed a significant down-regulation of hsa-let7b-5p and its precursor. hsa-let7f-5p was overexpressed, and SLC5A5 was strongly suppressed. HMGA2 was overexpressed, reflecting no correlation with its regulatory let7 miRNAs. PTC samples were characterized by up-regulation of hsa-let7b-5p, its precursor and hsa-let7f-5p. SLC5A5 was strongly suppressed in comparison with normal thyroid tissue. HMGA2 was overexpressed, as shown in FTC, also. ATC samples showed a similar miRNAs profile as PTC. In contrast with FTC and PTC, these patients showed a stable or up-regulated SLC5A5 and HMGA2. CONCLUSIONS: Expression of HMGA2 is not correlated with the regulatory let7 miRNAs. Interestingly, SLC5A5 was down-regulated in FTC and PTC. Its expression could be modulated by hsa-let-7f-5p. ATC showed a loss of SLC5A5/hsa-let7f-5p correlation. SLC5A5, in ATC, needs further investigation to clarify the genetic/epigenetic mechanism altering its expression.
PURPOSE:Thyroid cancer (TC), the most common endocrine malignancy, increases its incidence worldwide. MicroRNAs have been shown to be abnormally expressed in tumors and could represent valid diagnostic markers for patients affected by TC. Our aim was to analyze the expression of tumorsuppressor hsa-let7b-5p and hsa-let7f-5p, together with their predicted targets SLC5A5 (NIS) and HMGA2, in papillary (PTC), follicular (FTC) and anaplastic (ATC). METHODS: 8 FTC, 14 PTC, 12 ATC and three normal thyroid tissue samples were analyzed for the expression of pre-let7b, hsa-let7b-5p and hsa-let7f-5p as SLC5A5 and HMGA2 by RT-qPCR. Data were analyzed by REST 2008. RESULTS: FTC patients showed a significant down-regulation of hsa-let7b-5p and its precursor. hsa-let7f-5p was overexpressed, and SLC5A5 was strongly suppressed. HMGA2 was overexpressed, reflecting no correlation with its regulatory let7 miRNAs. PTC samples were characterized by up-regulation of hsa-let7b-5p, its precursor and hsa-let7f-5p. SLC5A5 was strongly suppressed in comparison with normal thyroid tissue. HMGA2 was overexpressed, as shown in FTC, also. ATC samples showed a similar miRNAs profile as PTC. In contrast with FTC and PTC, these patients showed a stable or up-regulated SLC5A5 and HMGA2. CONCLUSIONS: Expression of HMGA2 is not correlated with the regulatory let7 miRNAs. Interestingly, SLC5A5 was down-regulated in FTC and PTC. Its expression could be modulated by hsa-let-7f-5p. ATC showed a loss of SLC5A5/hsa-let7f-5p correlation. SLC5A5, in ATC, needs further investigation to clarify the genetic/epigenetic mechanism altering its expression.
Authors: Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen Journal: Oncologist Date: 2014-09-26
Authors: Paul J Lappinga; N Sertac Kip; Long Jin; Ricardo V Lloyd; Michael R Henry; Jun Zhang; Aziza Nassar Journal: Cancer Cytopathol Date: 2010-10-25 Impact factor: 5.284
Authors: Xavier M Keutgen; Filippo Filicori; Michael J Crowley; Yongchun Wang; Theresa Scognamiglio; Rana Hoda; Daniel Buitrago; David Cooper; Martha A Zeiger; Rasa Zarnegar; Olivier Elemento; Thomas J Fahey Journal: Clin Cancer Res Date: 2012-02-20 Impact factor: 12.531
Authors: Lisa Zhang; Yaqin Zhang; Amit Mehta; Myriem Boufraqech; Sean Davis; Jing Wang; Ze Tian; Zhiya Yu; Matthew B Boxer; Jeffrey A Kiefer; John A Copland; Robert C Smallridge; Zhuyin Li; Min Shen; Electron Kebebew Journal: Oncotarget Date: 2015-04-20
Authors: Yong Won Choi; Hyun-Ju Kim; Young Hwa Kim; So Hyun Park; Yong Jun Chwae; Jeonghun Lee; Euy Young Soh; Jang-Hee Kim; Tae Jun Park Journal: Exp Mol Med Date: 2014-11-07 Impact factor: 8.718
Authors: Blair B Madison; Arjun N Jeganathan; Rei Mizuno; Monte M Winslow; Antoni Castells; Miriam Cuatrecasas; Anil K Rustgi Journal: PLoS Genet Date: 2015-08-05 Impact factor: 5.917
Authors: Yateng Tie; Chong Chen; Yanli Yang; Zhen Qian; Hang Yuan; Huan Wang; Haili Tang; Yao Peng; Xilin Du; Bin Liu Journal: Oncol Lett Date: 2018-04-02 Impact factor: 2.967
Authors: Sabine Wächter; Alexander I Damanakis; Moritz Elxnat; Silvia Roth; Annette Wunderlich; Frederik A Verburg; Sebastian A Fellinger; Detlef K Bartsch; Pietro Di Fazio Journal: J Clin Med Date: 2018-03-21 Impact factor: 4.241
Authors: Sabine Wächter; Annette Wunderlich; Silvia Roth; Ioannis Mintziras; Elisabeth Maurer; Sebastian Hoffmann; Frederik A Verburg; Sebastian A Fellinger; Katharina Holzer; Detlef K Bartsch; Pietro Di Fazio Journal: J Clin Med Date: 2018-05-15 Impact factor: 4.241
Authors: Sabine Wächter; Annette Wunderlich; Brandon H Greene; Silvia Roth; Moritz Elxnat; Sebastian A Fellinger; Frederik A Verburg; Markus Luster; Detlef K Bartsch; Pietro Di Fazio Journal: Int J Mol Sci Date: 2018-07-17 Impact factor: 5.923